IMMUNIC, INC. - 8-K Filing
Immunic reported a first-quarter net loss of $32.6 million (or $1.08 per share) for the three months ended March 31, 2026, compared to a net loss of $25.5 million ($2.51 per share) in Q1 2025. The company raised $200 million upfront from an oversubscribed private placement with potential for up to $400 million total and expects these funds to support operations through late 2027. It also announced top-line data from its phase 3 ENSURE trials in relapsing multiple sclerosis is expected by year-end, with a U.S. NDA submission planned for mid-2027. (Items: 2.02 Results of Operations and Financial Condition On May 13 2026, Immunic, Inc, 9.01 Financial Statements and Exhibits Exhibit Description 99)
Tickers: $IMUX